Generic Name and Formulations:
Metaxalone 800mg; scored tabs.
King Pharmaceuticals, Inc.
Indications for SKELAXIN:
As adjunct treatment for acute, painful musculoskeletal conditions.
800mg 3–4 times daily.
≤12yrs: not established.
Anemias. Significant renal or hepatic dysfunction.
Renal or hepatic impairment (monitor LFTs). Elderly. Pregnancy, nursing mothers: not recommended.
Increased risk of sedation, respiratory depression with concomitant other CNS depressants (eg, alcohol, benzodiazepines, opioids, TCAs); monitor closely. Risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, SNRIs, TCAs, triptans, 5-HT3 antagonists, opioids, mirtazapine, trazodone, tramadol, MAOIs, linezolid, IV methylene blue); monitor and discontinue if suspected. Concomitant with food may enhance CNS depression. May cause false (+) Benedict's test.
Muscle relaxant (central).
Drowsiness, dizziness, headache, nervousness, GI upset, rash, jaundice, hemolytic anemia, leukopenia; hypersensitivity reactions.
Endocrinology Advisor Articles
- Efficacy and Safety of Alirocumab in Diabetes Mellitus
- Safety of DPP-IV Inhibitor, Cardiovascular Events After ACS in Type 2 Diabetes
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Does Maintenance of Certification Status Affect Patient Care?
- Emotional Hyper-Reactivity and Cardiometabolic Risk in Remitted Bipolar Disorder
- Reduced Mortality for Women Undergoing Assisted Reproduction Likely Due to "Healthy Patient Effect"
- Romosozumab Followed by Denosumab Effective for BMD Increase in Postmenopausal Women